Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report
Abstract
Background: The management of severe acute pancreatitis (SAP) complicated by multi-site infections with extensively drug-resistant Acinetobacter baumannii (XDR-AB) represents a critical therapeutic challenge. This report describes, to our knowledge, an early successful application of sulbactam-durlobactam in an SAP patient with concurrent XDR-AB infections in the abdomen, biliary tract and lungs.
Case presentation: A 36-year-old female with hypertriglyceridemic SAP developed infections at multiple sites, with cultures consistently yielding XDR-AB. After the failure of multiple last-line antimicrobial regimens, therapy was switched to sulbactam-durlobactam combined with meropenem. This change was followed by a substantial clinical improvement: body temperature normalized, infection biomarkers decreased significantly and microbiological clearance of XDR-AB from all sites was achieved, leading to successful liberation from mechanical ventilation and discharge from the ICU.
Conclusion: This case demonstrates that sulbactam-durlobactam can be a highly effective therapeutic option for achieving both clinical and microbiological cure in complex SAP cases with multi-site XDR-AB infections that are refractory to conventional treatment regimens. It contributes early real-world evidence supporting a new therapeutic strategy for managing such life-threatening, complex infections.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.